Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99


A Rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia.

Anampa-Guzmán A, Raez LE.

Cureus. 2018 Apr 24;10(4):e2525. doi: 10.7759/cureus.2525.


Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680-4. doi: 10.1016/j.jtho.2018.05.030. [Epub ahead of print] Review.


Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

Passiglia F, Raez LE, Rolfo C.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1076-S1080. doi: 10.21037/jtd.2018.03.92. No abstract available.


ROS-1 Rearrangements in Circulating Tumor Cells.

Raez LE, Manca P, Rolfo C, Singh V.

J Thorac Oncol. 2018 May;13(5):e71-e72. doi: 10.1016/j.jtho.2017.11.127. No abstract available.


Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A, Bretel D, Flores CJ, Rolfo C.

ESMO Open. 2018 Apr 13;3(3):e000344. doi: 10.1136/esmoopen-2018-000344. eCollection 2018.


Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625. doi: 10.1016/j.bbrc.2018.04.120. Epub 2018 Apr 30.


The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.

Raez LE, Cardona AF, Santos ES, Catoe H, Rolfo C, Lopes G, Barrios C, Mas LA, Vallejos C, Zatarain-Barrón ZL, Caglevic C, Arrieta O.

Lung Cancer. 2018 May;119:7-13. doi: 10.1016/j.lungcan.2018.02.014. Epub 2018 Mar 2. Review.


Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.

Castellanos-Rizaldos E, Grimm DG, Tadigotla V, Hurley J, Healy J, Neal PL, Sher M, Venkatesan R, Karlovich C, Raponi M, Krug A, Noerholm M, Tannous J, Tannous BA, Raez LE, Skog JK.

Clin Cancer Res. 2018 Jun 15;24(12):2944-2950. doi: 10.1158/1078-0432.CCR-17-3369. Epub 2018 Mar 13.


EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

Raez LE, Pinto JA, Schrock AB, Ali SM.

J Thorac Oncol. 2018 Mar;13(3):e33-e34. doi: 10.1016/j.jtho.2017.10.005. No abstract available.


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.


Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

Passiglia F, Caglevic C, Giovannetti E, Pinto JA, Manca P, Taverna S, Listì A, Gil-Bazo I, Raez LE, Russo A, Rolfo C.

Semin Cancer Biol. 2018 Jan 31. pii: S1044-579X(17)30218-3. doi: 10.1016/j.semcancer.2018.01.015. [Epub ahead of print] Review.


Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.

Pucci M, Reclusa Asiáin P, Duréndez Sáez E, Jantus-Lewintre E, Malarani M, Khan S, Fontana S, Naing A, Passiglia F, Raez LE, Rolfo C, Taverna S.

Target Oncol. 2018 Apr;13(2):175-187. doi: 10.1007/s11523-018-0551-8.


Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.

Castrellon AB, Velez M, Nguyen SM, Blaya M, Barnick S, Dumais K, LeCroy N, Raez LE.

Hematol Oncol Stem Cell Ther. 2018 Mar;11(1):30-33. doi: 10.1016/j.hemonc.2017.07.006. Epub 2017 Oct 28.


Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI, Raez LE.

Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.


Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

Schrock AB, Lai A, Ali SM, Miller VA, Raez LE.

J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017. No abstract available.


In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies.

Pinto JA, Rolfo C, Raez LE, Prado A, Araujo JM, Bravo L, Fajardo W, Morante ZD, Aguilar A, Neciosup SP, Mas LA, Bretel D, Balko JM, Gomez HL.

Sci Rep. 2017 May 8;7(1):1526. doi: 10.1038/s41598-017-01207-3.


The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.

Castrellon AB, Pidhorecky I, Valero V, Raez LE.

Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3. Review.


Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.

Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C.

ESMO Open. 2016 Jun 17;1(4):e000055. eCollection 2016. Review.


P1.29: "Real World" Use of Liquid Biopsy in Patients With Lung Adenocarcinoma and Correlation With Tumor Tissue Genetic Profile: Track: Advanced NSCLC.

Santos ES, Raez LE, Castillero L, Marana C, Hunis B.

J Thorac Oncol. 2016 Oct;11(10S):S199-S200. doi: 10.1016/j.jtho.2016.08.051. Epub 2016 Sep 22. No abstract available.


P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.

Raez LE, Santos ES, Mourafetis J, Kim AY, Hunis B, Sareli C, Castillero L, Velis E.

J Thorac Oncol. 2016 Oct;11(10S):S187-S188. doi: 10.1016/j.jtho.2016.08.035. Epub 2016 Sep 22. No abstract available.


PD2.01 (also presented as P1.13): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar.

Raez LE, Santos ES, Mourafetis J, Kim AY, Hunis B, Sareli C, Castillero L, Velis E.

J Thorac Oncol. 2016 Oct;11(10S):S176. doi: 10.1016/j.jtho.2016.08.016. Epub 2016 Sep 22. No abstract available.


Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America.

Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR.

Clin Lung Cancer. 2017 Jan;18(1):e71-e79. doi: 10.1016/j.cllc.2016.05.003. Epub 2016 Jun 5. Review.


BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

Caparica R, de Castro G Jr, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, Santos ES, Raez LE, Rolfo C.

Crit Rev Oncol Hematol. 2016 May;101:32-9. doi: 10.1016/j.critrevonc.2016.02.012. Epub 2016 Feb 27. Review.


The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.

Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C.

Expert Opin Investig Drugs. 2016;25(4):385-92. doi: 10.1517/13543784.2016.1152261. Epub 2016 Feb 24. Review.


Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.

Ruiz R, Raez LE, Rolfo C.

Expert Opin Investig Drugs. 2015;24(8):1101-9. doi: 10.1517/13543784.2015.1056779. Epub 2015 Jun 22. Review.


ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P.

Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Review.


Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.


Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.

Ruiz R, Hunis B, Raez LE.

Curr Oncol Rep. 2014 Sep;16(9):400. doi: 10.1007/s11912-014-0400-6. Review.


Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.

Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review.


Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.

Perez CA, Velez M, Raez LE, Santos ES.

Lung Cancer. 2014 May;84(2):110-5. doi: 10.1016/j.lungcan.2014.02.001. Epub 2014 Feb 8. Review.


Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.

Rolfo C, Raez LE, Russo A, Reguart N, Campelo RG, Bronte G, Papadimitriou K, Silvestris F.

Expert Opin Biol Ther. 2014 Jan;14(1):15-26. doi: 10.1517/14712598.2013.843667. Epub 2013 Oct 28. Review.


A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.


Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer.

Fabregas JC, Loaiza-Bonilla A, Talebi TN, Warsch S, Fernandez G, Raez LE, Santos ES.

Expert Rev Anticancer Ther. 2013 Sep;13(9):1065-72. doi: 10.1586/14737140.2013.829639. Review.


A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.

Lung Cancer. 2013 Sep;81(3):416-21. doi: 10.1016/j.lungcan.2013.06.002. Epub 2013 Jul 10.


Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ.

Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.


BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

Rolfo C, Raez LE, Bronte G, Santos ES, Papadimitriou K, Buffoni L, van Meerbeeck JP, Russo A.

Expert Opin Investig Drugs. 2013 Aug;22(8):1081-8. doi: 10.1517/13543784.2013.812630. Epub 2013 Jun 22. Review.


Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN.

J Clin Oncol. 2013 Apr 10;31(11):1415-21. doi: 10.1200/JCO.2012.46.3299. Epub 2013 Mar 4.


Therapeutic vaccines in non-small cell lung cancer.

Socola F, Scherfenberg N, Raez LE.

Immunotargets Ther. 2013 Sep 18;2:115-24. doi: 10.2147/ITT.S30813. eCollection 2013. Review.


A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.

Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ.

Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30. doi: 10.1007/s00280-012-2045-1. Epub 2012 Dec 11.


Emerging role of multikinase inhibitors for refractory thyroid cancer.

Perez CA, Arango BA, Velez M, Raez LE, Santos ES.

Biologics. 2012;6:257-65. doi: 10.2147/BTT.S24465. Epub 2012 Aug 8.


Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE.

Oral Oncol. 2012 Sep;48(9):887-92. doi: 10.1016/j.oraloncology.2012.03.020. Epub 2012 Apr 17.


Targeting the Met pathway in lung cancer.

Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES.

Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. doi: 10.1586/era.12.16. Review.


Epidermal growth factor vaccine in non-small-cell lung cancer.

Gonzalez Marinello GM, Santos ES, Raez LE.

Expert Rev Anticancer Ther. 2012 Apr;12(4):439-45. doi: 10.1586/era.12.24. Review.


Active immunotherapy for non-small-cell lung cancer: moving toward a reality.

Perez CA, Santos ES, Raez LE.

Expert Rev Anticancer Ther. 2011 Oct;11(10):1599-605. doi: 10.1586/era.11.155. Review.


The role of proteasome inhibition in nonsmall cell lung cancer.

Escobar M, Velez M, Belalcazar A, Santos ES, Raez LE.

J Biomed Biotechnol. 2011;2011:806506. doi: 10.1155/2011/806506. Epub 2011 May 4. Review.


Novel molecular targeted therapies for refractory thyroid cancer.

Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE.

Head Neck. 2012 May;34(5):736-45. doi: 10.1002/hed.21755. Epub 2011 May 4. Review.


Development of targeted therapy for squamous cell carcinomas of the head and neck.

Burgos-Tiburcio A, Santos ES, Arango BA, Raez LE.

Expert Rev Anticancer Ther. 2011 Mar;11(3):373-86. doi: 10.1586/era.10.193. Review.


Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.

Holt GE, Podack ER, Raez LE.

Therapy. 2011 Jan;8(1):43-54.

Supplemental Content

Support Center